Posts by: Alice Melão

News

Provenge (sipuleucel-T), a treatment approved in the U.S. for metastatic castration-resistant prostate cancer, significantly increased the number of patients alive at three years, compared to a placebo, a retrospective analysis ... Read more

February 11, 2019

University of Minnesota Team Receives $1M to Develop CAR-NK Therapy

News

The Prostate Cancer Foundation (PCF) has granted a $1 million Challenge Award to researchers from the Masonic Cancer Center at the University of Minnesota to support their investigations into new therapies ... Read more

February 7, 2019

HPN424 Shows Promising Safety, Immune Activation in Metastatic CRPC

News

Preliminary data from an ongoing Phase 1 trial suggest that Harpoon Therapeutics’ investigational therapy HPN424 is safe and effectively activates the immune system in metastatic castration resistant prostate cancer (mCRPC) patients. ... Read more

November 28, 2018

European Advisory Committee Recommends Approval of Erleada for Men at Risk of Prostate Cancer Spreading

News

Janssen‘s hormone therapy Erleada (apalutamide) may soon be used in Europe for men with castration-resistant prostate cancer (CRPC) who have a high risk of their disease spreading, after the Committee for Medicinal ... Read more

November 14, 2018

Phase 3 Trial of Relugolix for Advanced Prostate Cancer Completes Patient Enrollment

News

A Phase 3 trial evaluating Myovant Sciences’ relugolix as a treatment for advanced prostate cancer patients who are sensitive to androgen deprivation treatments has completed patient enrollment, the company announced. The randomized ... Read more

November 8, 2018

Phase 2 Trial of Irofulven to Treat Metastatic Castration-Resistant Prostate Cancer Opens in Denmark

News

Oncology Venture announced that patient enrollment has begun in a Phase 2 study evaluating irofulven as a possible treatment for metastatic castration-resistant prostate cancer (mCRPC). Specifically, the trial (NCT03643107) is for patients who ... Read more

October 11, 2018

OncBioMune Readies for Enrollment in Phase 2 Trial of ProscaVax Vaccine

News

OncBioMune Pharmaceuticals soon will initiate a Phase 2 trial evaluating the effectiveness and safety of its lead immunotherapy, ProscaVax, for men with early-stage prostate cancer. In a recent update, the company announced that ... Read more

September 10, 2018September 10, 2018

Patient Death in Phase 2b Prostate Cancer Trial Unrelated to Topsalysin, Sophiris Says

News

Topsalysin (PRX302), an investigative agent for localized prostate cancer, is unlikely to have caused the death of a patient in a Phase 2b trial testing the medicine, Sophiris Bio announced. A review of clinical ... Read more

July 9, 2018

Prostreat Seen as Better Than Current Therapies at Stopping Aggressive Prostate Cancer in Mice

News

NucleoBio’s investigative therapy Prostreat was seen to be better at preventing the growth and spread of metastatic castration-resistant prostate cancer than currently available hormone therapies, a mouse study showed. The ... Read more

May 2, 2018May 2, 2018

FDA Clears First Clinical Study of OBI-3424 in Prostate and Other Cancers

News

OBI Pharma is launching a Phase 1/2 trial in the United States to evaluate the safety and effectiveness of using OBI-3424 to treat solid cancers that are positive for the AKR1C3 enzyme. ... Read more